Sly L - Search Results

1

Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein.

Kobayashi DT, Decker D, Zaworski P, Klott K, McGonigal J, Ghazal N, Sly L, Chung B, Vanderlugt J, Chen KS. Kobayashi DT, et al. Among authors: sly l. PLoS One. 2012;7(11):e50763. doi: 10.1371/journal.pone.0050763. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226377 Free PMC article.

2

Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses.

Kobayashi DT, Olson RJ, Sly L, Swanson CJ, Chung B, Naryshkin N, Narasimhan J, Bhattacharyya A, Mullenix M, Chen KS. Kobayashi DT, et al. Among authors: sly l. PLoS One. 2011;6(8):e24269. doi: 10.1371/journal.pone.0024269. Epub 2011 Aug 31. PLoS One. 2011. PMID: 21904622 Free PMC article.

3

Hydrocortisone inhibits IFN-γ production in equine, ovine, and bovine PBMCs.

McCandless EE, Rai SK, Mwangi D, Sly L, Franz LC. McCandless EE, et al. Among authors: sly l. Vet Immunol Immunopathol. 2013 May 15;153(1-2):128-33. doi: 10.1016/j.vetimm.2012.12.012. Epub 2013 Jan 3. Vet Immunol Immunopathol. 2013. PMID: 23351642

4

Pulmonary and systemic responses to aerosolized lysate of Staphylococcus aureus and Escherichia coli in calves.

Bassel LL, Co C, Macdonald A, Sly L, McCandless EE, Hewson J, Tiwari R, Sharif S, Siracusa L, Clark ME, Caswell JL. Bassel LL, et al. Among authors: sly l. BMC Vet Res. 2020 May 29;16(1):168. doi: 10.1186/s12917-020-02383-7. BMC Vet Res. 2020. PMID: 32471444 Free PMC article.

5

Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs.

Krautmann M, Walters RR, King VL, Esch K, Mahabir SP, Gonzales A, Dominowski PJ, Sly L, Mwangi D, Foss DL, Rai S, Messamore JE, Gagnon G, Schoell A, Dunham SA, Martinon OM. Krautmann M, et al. Among authors: sly l. Vet Immunol Immunopathol. 2023 Apr;258:110574. doi: 10.1016/j.vetimm.2023.110574. Epub 2023 Feb 21. Vet Immunol Immunopathol. 2023. PMID: 36842258 Free article.

6

Macrophage immunotherapy: overcoming impediments to realize promise.

Sly LM, McKay DM. Sly LM, et al. Trends Immunol. 2022 Dec;43(12):959-968. doi: 10.1016/j.it.2022.10.002. Epub 2022 Oct 29. Trends Immunol. 2022. PMID: 36441083 Review.

7

Evidence that oral immunoglobulins (KMP01) suppress pro-tumor inflammation in rectal carcinoma: Case report and treatment concept.

Oguz S, Buia A, Albers B, Suna K, Piroski V, Knapp A, Sly L, Döll U, Braun P, Woodcock BG. Oguz S, et al. Among authors: sly l. Int J Clin Pharmacol Ther. 2022 Dec;60(12):521-529. doi: 10.5414/CP204326. Int J Clin Pharmacol Ther. 2022. PMID: 36331015

8

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.

Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Luzentales-Simpson M, et al. Among authors: sly lm. Front Cell Dev Biol. 2021 Feb 3;9:612830. doi: 10.3389/fcell.2021.612830. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33614645 Free PMC article. Review.

9

COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (Primum nil nocere).

Sly LM, Braun P, Woodcock BG. Sly LM, et al. Int J Clin Pharmacol Ther. 2020 Dec;58(12):678-686. doi: 10.5414/CP203890. Int J Clin Pharmacol Ther. 2020. PMID: 33141018

10

Gut microbes in pediatric ALL survivorship.

Sly LM. Sly LM. Pediatr Hematol Oncol. 2020 Sep;37(6):451-454. doi: 10.1080/08880018.2020.1793850. Epub 2020 Jul 23. Pediatr Hematol Oncol. 2020. PMID: 32701381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page